

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PASSING OF CONSISTENCY EVALUATION FOR “QIMAITE” (TRAMADOL HYDROCHLORIDE TABLETS)

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group’s “**Qimaite**” (tramadol hydrochloride tablets (50mg)) (the “**Drug**”) has been granted approval by the China Food and Drug Administration for passing the consistency of quality and efficacy evaluation of generic drugs (the “**Consistency Evaluation**”). The Group is the first one passing the Consistency Evaluation for this type of drug in China.

Tramadol hydrochloride tablet is a pain medication of the non-morphine variety. It is mainly used for the treatment of adult pains which are severe as to require the use of opioid analgesics and have inadequate alternative therapy

Tramadol hydrochloride tablet is one of the key analgesics of the Group. It has been launched in the U.S. market after obtaining the ANDA (Abbreviated New Drug Application) approval in 2013. The drug also has a leading market share of the same type of drug in China. The passing of the Consistency Evaluation proves the consistency of the Drug with the originator drug in terms of quality and efficacy, indicating its availability as a clinical alternative for the originator drug and providing a medication option of good quality and competitive price for patients.

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 21 May 2018

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. WANG Zhenguo, Mr. WANG Jinxu, Mr. LU Hua, Mr. LI Chunlei and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.